Catalyst
Slingshot members are tracking this event:
ABT-493 and ABT-530 Phase 3 Data to be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 11-15, 2016 in Boston
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ENTA | Community voting in process | |||||
Additional Information
Enata Pharmaceuticals launched its ENDURANCE and EXPEDITION studies of 6 Phase 3 trials to "evaluate the investigational treatment of a once-daily, co-formulated combination of ABT-493 and ABT-530 in patients infected with genotypes 1-6 of hepatitis C infection". As soon as the dosing begins, the studies will last approximately 12 weeks, with a couple only lasting 8 weeks. Dosing was originally expected to begin in Q1 and the Phase 3 data to be released around mid-2016.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 15, 2016
Occurred Source:
http://ir.enanta.com/phoenix.zhtml?c=147990&p=irol-newsArticle&ID=2222520
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3 Study, Hepatitis C, Abt-493, Abt-530
